Siren L.L.C. Invests $17.10 Million in Amylyx Pharmaceuticals, Inc. $AMLX

Siren L.L.C. purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,230,000 shares of the company’s stock, valued at approximately $17,097,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. KBC Group NV acquired a new stake in Amylyx Pharmaceuticals during the first quarter valued at approximately $26,000. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals during the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd grew its position in shares of Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after acquiring an additional 3,493 shares in the last quarter. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $28,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Amylyx Pharmaceuticals by 54.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after acquiring an additional 1,890 shares during the last quarter. 95.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares in the company, valued at $3,555,728.80. This represents a 7.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AMLX shares. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Mizuho lifted their price objective on shares of Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a report on Monday. Guggenheim boosted their target price on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Friday, May 8th. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.62.

Amylyx Pharmaceuticals Stock Down 0.6%

Shares of AMLX stock opened at $17.59 on Friday. The company has a market cap of $1.96 billion, a P/E ratio of -11.73 and a beta of -0.20. The business has a 50 day moving average of $15.78 and a two-hundred day moving average of $15.14. Amylyx Pharmaceuticals, Inc. has a 52 week low of $7.48 and a 52 week high of $19.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.4 EPS for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.